Y-mAbs Therapeutics, Inc.
YMAB
$8.53
$0.010.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 85.39M | 88.66M | 87.69M | 84.55M | 86.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 85.39M | 88.66M | 87.69M | 84.55M | 86.55M |
| Cost of Revenue | 15.80M | 16.11M | 15.25M | 9.45M | 9.85M |
| Gross Profit | 69.58M | 72.55M | 72.43M | 75.11M | 76.70M |
| SG&A Expenses | 49.12M | 55.07M | 53.93M | 53.37M | 50.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.82M | 116.28M | 116.60M | 112.30M | 114.19M |
| Operating Income | -23.44M | -27.62M | -28.91M | -27.75M | -27.65M |
| Income Before Tax | -22.62M | -28.53M | -29.81M | -23.06M | -23.97M |
| Income Tax Expenses | -394.00K | -301.00K | -146.00K | 801.00K | 642.00K |
| Earnings from Continuing Operations | -22.22 | -28.23 | -29.67 | -23.86 | -24.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.22M | -28.23M | -29.67M | -23.86M | -24.61M |
| EBIT | -23.44M | -27.62M | -28.91M | -27.75M | -27.65M |
| EBITDA | -23.09M | -27.17M | -28.38M | -27.15M | -27.00M |
| EPS Basic | -0.49 | -0.63 | -0.67 | -0.54 | -0.56 |
| Normalized Basic EPS | -0.27 | -0.36 | -0.39 | -0.32 | -0.34 |
| EPS Diluted | -0.50 | -0.63 | -0.67 | -0.54 | -0.56 |
| Normalized Diluted EPS | -0.27 | -0.36 | -0.39 | -0.32 | -0.34 |
| Average Basic Shares Outstanding | 179.92M | 178.63M | 177.30M | 176.06M | 175.05M |
| Average Diluted Shares Outstanding | 179.92M | 178.63M | 177.30M | 176.06M | 175.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |